Business
Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing
Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long...
About this update from Vector Science And Therapeutics Corp.
[{"type":"text","content":"\n\n\nVector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nVector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing\nCanada NewsWire\n\n\nOption agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade FormulationsMEQUON, Wis., May 13, 2026 /CNW/ -- Vector Science & Therapeutics (TSXV: PAIN) (\"Vector\" or the \"Company\") today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash payments over time, from treasury for of up to US$1,000,000 (the \"Option\"). The option is exercisable over a three-year period. LyoGenesis Plus has entered into an agreement to acquire MPP Group LLC (\"MPP\"), an FDA-registered, cGMP-compliant contract development and manufacturing organization headquartered in Mequon, Wisconsin. If exercised in its entirety over the three years, the Option would give Vector a 15% ownership interest in MPP, securing a long-term pharmaceutical-grade manufacturing platform for Vector's growing portfolio of peptide formulations and drug delivery products.\n\n\n\n\n\n\n\nKey HighlightsFDA-Registered, cGMP Manufacturing — MPP operates a modern 35,000 sq. ft. facility in Mequon, Wisconsin, equipped with sophisticated analytical instrumentation. The Option gives Vector an ownership stake through LyoGenesis in this infrastructure without the cost or time required to build a comparable facility.22 Novel Peptide Formulations — Vector and MPP will jointly develop shelf-stable peptide formulations with a target stability of up to 24 months, including 14 peptides recently removed from the FDA Category 2 list.Capital Leverage Through LyoGenesis Plus — LyoGenesis Plus is well-capitalized with a $2 million equipment line of credit and a $1 million accounts receivable facility, giving Vector non-dilutive access...